PYC Therapeutics is a clinical-stage biotech company that targets the underlying drivers of genetic diseases. We combine scientific rigour, clinical insights and a proprietary drug delivery platform to create therapies that treat genetic diseases for which there are limited, if any, treatment options available. Our purpose is to change lives.
RNA therapies are molecular treatments which modulate the production of proteins that are low or missing in the body.
Traditional RNA treatments are limited by their inability to cross the cell membrane and deliver the therapeutic to the inside of the target cell. To date, this drug delivery challenge has restricted the number of diseases RNA therapies can treat. By binding our uniquely designed RNA therapies with our proprietary therapeutic delivery platform of cell-penetrating peptides (CPPs), we have overcome this challenge to achieve greater intracellular RNA potency to treat disease – it’s genuinely life-changing science.
Targeting genetic diseases with no treatment options available today
Focusing on our goal to treat, and potentially cure, inherited diseases
Be part of the future of truly differentiated RNA therapeutics
For more detailed information on financial performance, shareholder services and more, please visit our dedicated investor information sub-page.
